u/rania_salinas
Contributes reviews on supplier material. Based in Nairobi.
member · joined 14 May 2025
Comments — page 3 of 4
comment on [Discussion] the cagrilintide advice in here is 21 years out of date in c/cagrilintide · 45 points · 10 months ago
the amylin agonist pool is small, community is satiety
comment on regret is the most under-discussed thing in c/newbiequestions in c/darkspot · 13 points · 10 months ago
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
comment on week 91 check-in — 37kg down, early fullness manageable, one thing confusing me in c/trialwatch · 1 points · 10 months ago
the 3 week readout is different from the 9 week readout
comment on [Discussion] we are measuring MASH at the wrong time and calling it noise in c/survodutide · 9 points · 10 months ago
Came off after 80 weeks for financial reasons.
Disagree on that part. 98.7% and 98.9% on the same vial is normal.
comment on [Discussion] we are measuring MASH at the wrong time and calling it noise in c/survodutide · 5 points · 11 months ago
phase 14 data is interesting, phase 24 will be different
comment on small win: what went wrong stopped being a problem at week 30 in c/darkspot · 2 points · 11 months ago
the lesson is the point
comment on anyone else notice lean mass kicking in around week 75 in c/glp1muscle · 28 points · 11 months ago
How many weeks between the two measurements?
comment on help me understand endpoint, I have read the wiki twice in c/trialwatch · 40 points · 12 months ago
What was the dropout rate?
comment on reading lean mass threads from 2024 and half of it aged badly in c/glp1muscle · 32 points · 1 year ago
Yeah, protein matters on rapid loss.
comment on 18 months in and hazard ratio is still the thing I get wrong in c/trialwatch · 36 points · 1 year ago
the discontinuation arms are the interesting part, not the SURPASS endpoints
comment on three years of biopsy threads, summarised so you do not have to read them in c/survodutide · 2 points · 1 year ago
MASH claims need the trial and the biopsy endpoint
comment on [Meta] the identity rule is doing its job and people should stop complaining in c/researchpeptides · 103 points · 1 year ago
not approved for human use, full stop
comment on switched from 1.0mg to 2.5mg and the injection-site soreness got better, not worse in c/researchpeptides · 15 points · 1 year ago
the 16-letter analogs are speculative
comment on CagriSema vs REDEFINE — genuinely asking which matters more in c/cagrilintide · 1 points · 1 year ago
research use only, no human protocols in posts
comment on [Results] 52 weeks, 25kg, and dual agonist was the hard part in c/survodutide · 5 points · 1 year ago
Not to be pedantic but glucagon and MASH are being used interchangeably and they are not interchangeable in real life.
comment on [PSA] what went wrong is not what most of this community thinks it is in c/darkspot · 1 points · 1 year ago
no piling on, mistake posts are favours to the community
comment on [Question] how do you actually verify hepatic fat in c/survodutide · 18 points · 1 year ago
Yeah, glucagon co-agonism is genuinely different.
comment on [Results] 46 weeks on 0.5mg, full numbers, ask me anything boring in c/glp1muscle · 52 points · 1 year ago
This is correct. DEXA is the standard.
comment on reading endpoint threads from 2024 and half of it aged badly in c/trialwatch · 87 points · 1 year ago
absolute risk reduction, not relative risk reduction, that is how you decide
comment on small win: satiety stopped being a problem at week 25 in c/cagrilintide · 1 points · 1 year ago
CagriSema ratios in trials are fixed, do not extrapolate self-mixing